Sustained virological response to peginterferon therapy in patients infected with HCV (genotypes 2 and 3), with or without HIV

• Published in: BMC infectious diseases 2014-09, Vol.14 Suppl 5 (S5), p.S4-S4, Article S4
• Main Authors: Odolini, Silvia, Amadasi, Silvia, Cerini, Carlo, Giralda, Mariarosaria, Nasta, Paola, Castelli, Francesco
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antiviral Agents - therapeutic use; Coinfection - drug therapy; Coinfection - virology; Drug therapy; Epidemiology; Female; Genotype; Hepacivirus - drug effects; Hepacivirus - genetics; Hepacivirus - isolation & purification; Hepatitis; Hepatitis C - drug therapy; Hepatitis C - virology; Hepatitis C virus; HIV; HIV Infections - drug therapy; HIV Infections - virology; HIV-1 - physiology; Hospitals; Human immunodeficiency virus; Humans; Infections; Interferon-alpha - therapeutic use; Liver diseases; Male; Middle Aged; Mortality; Polyethylene Glycols - therapeutic use; Recombinant Proteins - therapeutic use; Retrospective Studies; Ribavirin - therapeutic use; Studies; Treatment Outcome; Tropical diseases; Viral Load
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/1471-2334-14-S5-S4

HIV infection leads to a faster progression of liver disease in subjects infected with HCV, as compared with HCV mono-infected patients. Previous reports suggest that sustained virological response (SVR) rates are lower in HIV/HCV coinfection than in HCV monoinfection. We aimed to compare SVR rates of these two populations. We retrospectively analyzed clinical, biochemical and virological data of HCV and HIV/HCV infected patients with HCV genotypes 2 and 3 who started anti-HCV treatment between March 2004 and November 2012, at a single large center. Intention-to-treat (ITT) and per-protocol (PP) analysis were performed. Univariate and multivariate logistic regression analyses were performed to assess predictors of SVR. 461 patients were analyzed: 307 (66.6%) males, 76 (16.5%) infected with HIV. Several differences at baseline between HCV monoinfected and HIV/HCV coinfected patients were observed. HCV monoinfected group was characterized by higher prevalence of genotype 2 (53% vs 5.3%), higher baseline HCV viral load (50% vs 35%), shorter mean duration of treatment (19 vs 41 weeks), more frequent use of peginterferon alfa-2a (84.5% vs 69.7%), lower prevalence of cirrhosis (6% vs 31.6%). Globally, SVR was achieved by 353 (76.6%) patients and 321 (83.8%) in the PP analysis. No statistically relevant differences were found in SVR rates between the two groups, either in ITT [78.2% (n = 301/385) vs 68.4% (n = 52/76), p =0.066, respectively] than in PP analysis [83.6% (n = 276/330) vs 84.9% (n = 45/53), p = 0.8]. Higher baseline viral loads and interruption of peginterferon and/or ribavirin were associated with a poor outcome of anti-HCV treatment while HIV infection was not related to major or minor probability to achieve SVR.